# Perinucleolar compartment

The perinucleolar compartment (PNC) is a membraneless subnuclear body attached to the periphery of the nucleolus, enriched in a subset of [RNA polymerase III](https://www.edgepedia.org/rna-polymerase-iii) (pol III) transcribed noncoding RNAs and RNA-binding proteins, that forms predominantly in cancer cells and correlates with metastatic behavior.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup><sup> • </sup><sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup> It was first observed in 1992 as a perinucleolar focus of the polypyrimidine tract-binding protein (PTB, also called hnRNP I or PTBP1) and named in 1995 after Matera and colleagues found several pol III transcripts concentrated in the same structure.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)</sup>

| Key fact | Detail |
|---|---|
| Size and shape | Irregularly shaped body, 0.25 to 4 µm in length, closely associated with but structurally distinct from the nucleolus<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup> |
| Ultrastructure | Multiple electron-dense strands, each about 80–180 nm in diameter, forming a reticulated meshwork on part of the nucleolar surface<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)</sup> |
| RNA content | A subset of pol III noncoding RNAs: RNase MRP RNA, RNase P RNA, hY RNAs, Alu RNA, and SRP (7SL) RNA; U6, tRNA, 7SK, and 5S RNA are not detected there<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup> |
| Protein content | RNA-binding proteins active in pol II RNA metabolism: PTB, CUG-BP, KSRP, Raver1, Raver2, Rod1, and nucleolin<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup> |
| Transcription dependence | Structural integrity depends on RNA polymerase III transcription; inhibition of pol II does not disrupt the structure<sup>[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC3057709/)</sup> |
| Cell-cycle behavior | Disassembles at the start of mitosis, reassembles in late telophase, and is commonly heritable with similar shape, size, and number in daughter cells<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup> |
| Cancer association | Prevalence is 0% in normal breast tissue and rises to near 100% in distant metastasis; prevalence and number per nucleus correlate with metastatic potential and inversely with patient survival<sup>[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374481/)</sup><sup> • </sup><sup>[6](https://cshperspectives.cshlp.org/content/14/7/a041268.full)</sup> |

## Structure and dynamics

The PNC sits on the nucleolar surface as a highly interconnected reticulated mesh. Three-dimensional reconstruction from serial electron microscope sections shows thick strands, some in direct contact with the nucleolus, with considerable cell-to-cell variability: in some cells the body lies mostly on the nucleolar surface, in others it extends into the nucleolus like a plug, and occasionally part of the nucleolus extends into the PNC.<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)</sup>

**A dynamic body.** Live-cell imaging of cells expressing green fluorescent protein-tagged PTB shows small, distinct movements along the nucleolar periphery over time.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)</sup> [Fluorescence](https://www.edgepedia.org/fluorescence) recovery after photobleaching (FRAP) shows that PTB turns over rapidly within the PNC, with bleached fluorescence recovering within about 5 minutes, indicating continuous exchange of components with the surrounding nucleoplasm.<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)</sup><sup> • </sup><sup>[8](https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.22107)</sup> The PNC persists throughout interphase, disassembles when nucleoli dissociate at the beginning of mitosis, and reassembles in late telophase as nucleoli reform.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup>

## Molecular composition

The known PNC-associated proteins are all RNA-binding proteins implicated in the metabolism of [RNA polymerase II](https://www.edgepedia.org/rna-polymerase-ii) transcripts: PTB, CUG-binding protein (CUG-BP), KH-type splicing regulatory protein (KSRP), Raver1, Raver2, Rod1, and nucleolin.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup> PTB is a 57-kD protein that binds pyrimidine-rich RNA sequences and participates in pre-mRNA splicing, alternative splice site selection, polyadenylation, and translational regulation; at least three of its RNA recognition motifs are required for it to localize to the PNC, indicating that RNA binding is necessary for its targeting.<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)</sup>

The RNAs enriched in the PNC are, for the most part, small noncoding RNAs transcribed by pol III, but they also include PNCTR, a long noncoding RNA transcribed by pol I, which is unexpected because the resident proteins normally act on pol II transcripts.<sup>[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10824145/)</sup> Enriched RNAs include RNase MRP RNA, RNase P RNA, hY RNAs, Alu RNA, and signal recognition particle (7SL) RNA.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup><sup> • </sup><sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup> Not all pol III transcripts accumulate there: in situ hybridization finds no enrichment of U6 snRNA, tRNA, 7SK, or 5S RNA, and searches for pre-mRNA and pol I transcribed ribosomal RNAs have not detected them in the PNC either.<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup>

**Enrichment is not explained by overexpression.** Overexpressing PTB or CUG-BP alone, or together with PNC-associated RNAs such as MRP RNA and RNase P RNA, does not induce PNC formation in primary or immortalized cells, so the compartment's assembly requires more than simply raising the concentration of its known components.<sup>[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)</sup>

## Relationship to transcription

The PNC is itself a site of transcription. In permeabilized cells it incorporates Br-UTP and FITC-conjugated CTP within 5 minutes of pulse labeling; selective inhibition of [RNA polymerase I](https://www.edgepedia.org/rna-polymerase-i) does not appreciably affect this incorporation, while inhibition of all RNA polymerases with actinomycin D blocks it completely, pointing to pol II and/or pol III activity within the body.<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)</sup> The compartment's structural integrity depends on RNA polymerase III transcription, and RNA pol II inhibition does not disrupt PNC structure.<sup>[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC3057709/)</sup> [Immunolabeling](https://www.edgepedia.org/immunolabeling) also places poly(A) RNA and pre-mRNA processing factors, including splicing factors and the 3′ end processing factor PAB II, in the PNC in addition to their nucleoplasmic distribution.<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)</sup>

Chemical and cell biology studies further indicate that the PNC is associated with a specific DNA locus. The nucleation of the PNC on such a locus could mean the locus transcribes a yet-to-be-identified PNC-associated RNA, or that the PNC regulates gene expression there.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)</sup> In 2025, researchers reported that the PNC and oncogenic super-enhancers are part of the same phase-separated structure containing phosphatidylinositol 4,5-bisphosphate (PIP2) and the long noncoding RNA HANR, which colocalizes with PIP2 near the nucleolus.<sup>[9](https://pubmed.ncbi.nlm.nih.gov/39648081/)</sup>

## The PNC in cancer

The PNC is predominantly present in cancer cells and is rarely observed in normal primary cells; surveys of many cell lines and primary cells have not detected PNCs in primary cells, including human and mouse embryonic stem cells.<sup>[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)</sup><sup> • </sup><sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup> [Prevalence](https://www.edgepedia.org/prevalence), defined as the percentage of nonmitotic, nonapoptotic cells containing at least one PNC, varies widely across cancer cell lines, from less than 5% to nearly 100%.<sup>[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10824145/)</sup>

**Prevalence tracks disease progression.** In breast cancer tissue, PNC prevalence is 0% in normal breast tissue and increases along with disease progression from benign lesions, to ductal carcinoma in situ, to affected lymph nodes, reaching near 100% in distant metastasis.<sup>[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374481/)</sup> High PNC prevalence in primary breast tumors is associated with higher incidence of distant metastases, and prevalence is negatively correlated with patient outcomes in the three cancer types examined; in colorectal carcinoma, in vivo analysis of tumor tissues shows a close correlation between PNC prevalence and disease progression, with high prevalence associated with poor patient outcome.<sup>[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10824145/)</sup><sup> • </sup><sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup> Detection of the PNC noncoding RNA PNCTR reveals highly expressed PNCs in metastatic lymph nodes.<sup>[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10824145/)</sup>

## Drug development

Because PNC presence correlates with metastatic behavior in vitro and in vivo, the compartment has been used as a phenotypic readout for metastasis-selective compound screens. A high-content screen of over 140,000 structurally diverse compounds, using PNC prevalence as the marker, identified metarrestin, a PNC inhibitor that suppressed metastatic development and extended survival in several mouse cancer models.<sup>[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176865/)</sup><sup> • </sup><sup>[6](https://cshperspectives.cshlp.org/content/14/7/a041268.full)</sup> Chemical biology studies have also shown that PNC structure can be disassembled by a large array of genotoxic drugs.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)</sup>

## Function

The precise function of the PNC remains under investigation. The evidence supports a working model in which novel RNA–protein complexes at the PNC regulate gene expression in cancer cells, possibly at specific chromatin sites.<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)</sup> Sequestration of PTBP1 in the PNC has been proposed to help cancer cells avoid programmed cell death, since PTBP1 has been reported to have pro-apoptotic activities.<sup>[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10824145/)</sup> Its strong association with the metastatic phenotype, independent of any settled mechanism, has made the PNC both a prognostic marker for solid tumors and a screening target in anti-cancer drug development.<sup>[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)</sup><sup> • </sup><sup>[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176865/)</sup>

## References

1. [Pollock C, Huang S (2010). The Perinucleolar Compartment. Cold Spring Harbor Perspectives.](https://pmc.ncbi.nlm.nih.gov/articles/PMC2828281/)
2. [Structure and Function of the Perinucleolar Compartment in Cancer Cells. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374480/)
3. [The Perinucleolar Compartment. PMC (2008).](https://pmc.ncbi.nlm.nih.gov/articles/PMC2808188/)
4. [Characterization of MRP RNA–protein interactions within the perinucleolar compartment. PMC (2010).](https://pmc.ncbi.nlm.nih.gov/articles/PMC3057709/)
5. [The Perinucleolar Compartment: RNA Metabolism and Cancer. PMC (2014).](https://pmc.ncbi.nlm.nih.gov/articles/PMC4374481/)
6. [Nuclear Compartments: An Incomplete Primer. Cold Spring Harbor Perspectives in Biology (2022).](https://cshperspectives.cshlp.org/content/14/7/a041268.full)
7. [Huang S, Deerinck TJ, Ellisman MH, Spector DL (1998). The Perinucleolar Compartment and Transcription. J Cell Biol 143(1):35–47.](https://pmc.ncbi.nlm.nih.gov/articles/PMC2132804/)
8. [Journal of Cellular Biochemistry: perinucleolar compartment dynamics. Wiley.](https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.22107)
9. [The perinucleolar compartment and the oncogenic super-enhancers are part of the same phase-separated structure filled with PIP2 and lncRNA HANR. PubMed (2025).](https://pubmed.ncbi.nlm.nih.gov/39648081/)
10. [The perinucleolar compartment: structure, function, and utility in anti-cancer drug development. PMC (2024).](https://pmc.ncbi.nlm.nih.gov/articles/PMC10824145/)
11. [Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. PMC (2018).](https://pmc.ncbi.nlm.nih.gov/articles/PMC6176865/)

---
*Topic: Encyclopedia › Life and health › Biological foundations › RNA and gene regulation › RNA processing, modification, and translation › Transfer RNA, ribosomal RNA, and translation › Ribosomal RNA and ribosome biogenesis › Nucleolus and ribosome biogenesis compartment*

*Initially written Sep 17, 2026 · Reviewed: Oct 21, 2026 · Edited: Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*

*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*

License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license
